Arrowhead Pharmaceuticals Inc
NASDAQ:ARWR

  • LAST PRICE
    21.2850
  • TODAY'S CHANGE (%)
    2.4950 (13.2783%)
  • Bid / Lots
    21.2600/ 7
  • Ask / Lots
    21.3200/ 7
  • Open / Previous Close
    22.9500 / 18.7900
  • Day Range
    20.8470
    24.2300
  • 52 Week Range
    17.0500
    39.8300
  • Volume
    6,332,663

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
ARWR
Arrowhead Pharmaceuticals Inc
2.3B
-4.6x
---
MIRM
Mirum Pharmaceuticals Inc
2.1B
-21.3x
---
TWST
Twist Bioscience Corp
2.5B
-12.8x
---
MNKD
MannKind Corp
1.9B
92.9x
---
DVAX
Dynavax Technologies Corp
1.6B
104.1x
---
ZLAB
Zai Lab Ltd
3.0B
-9.9x
---
As of 2024-11-26

Company Information

Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 14 clinical-stage investigational medicines (nine wholly owned and five partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MUC5AC, ARO-MMP7, GSK-4532990, Fazirsiran, JNJ-3989, HZN-457, ARO-C3, ARO-PNPLA3, ARO-DUX4 and ARO-SOD1.

Contact Information

Headquarters
177 E Colorado Blvd, Suite 700PASADENA, CA, United States 91105
Phone
626-696-4702
Fax
626-304-3401

Executives

Independent Chairman of the Board
Douglass Given
President, Chief Executive Officer, Director
Christopher Anzalone
Chief Financial Officer
Kenneth Myszkowski
Chief Operating Officer, General Counsel, Company Secretary
Patrick O'Brien
Chief of Discovery and Translational Medicine
James Hamilton

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$2.3B
Revenue (TTM)
$19.6M
Shares Outstanding
124.3M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.81
EPS
$-4.65
Book Value
$2.53
P/E Ratio
-4.6x
Price/Sales (TTM)
117.3
Price/Cash Flow (TTM)
---
Operating Margin
-2,785.05%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.